Shares of biotechnology company Revolution Medicines (NASDAQ: RVMD) have surged more than 134% so far this year. Billionaire investor Stanley Druckenmiller's Duquesne Family Office drew attention to the stock by buying 316,000 shares of Revolution in the first quarter. The move has paid off for Druckenmiller, as the stock is up more than 105% since his purchase. Continue »Druckenmiller isn't the only wealthy investor high on the stock, as BlackRock and Vanguard own significant shares of Revolution. In colorectal cancer, the company is conducting early-stage studies and plans to announce the results of a combination study later this year.